Codexis (CDXS) Total Non-Current Liabilities (2010 - 2026)
Codexis (CDXS) recorded quarterly Total Non-Current Liabilities of $84.8 million in Q1 2026, down 11.61% quarter-over-quarter from $95.9 million in Q4 2025, and up 8.75% on a YoY basis from $78.0 million in Q1 2025.
Codexis (CDXS) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Codexis' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $84.8 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 8.75% year-over-year to $84.8 million; the TTM figure through Mar 2026 stood at $84.8 million (up 8.75% YoY), while the FY2025 annual figure was $95.9 million, up 18.72% from the prior year.
- Total Non-Current Liabilities was $84.8 million for Q1 2026 at Codexis, down from $95.9 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $104.2 million in Q4 2022 to a low of $48.7 million in Q4 2023.
- Historically, Total Non-Current Liabilities has averaged $78.4 million across 5 years, with a median of $79.8 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities plunged 53.26% in 2023, then jumped 65.9% in 2024.
- A 5-year view of Total Non-Current Liabilities shows it stood at $104.2 million in 2022, then slumped by 53.26% to $48.7 million in 2023, then surged by 65.9% to $80.8 million in 2024, then rose by 18.72% to $95.9 million in 2025, then retreated by 11.61% to $84.8 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $84.8 million (Q1 2026), $95.9 million (Q4 2025), and $84.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 64.76 Mn |
| 10 | Codexis | 236.00 Mn | 170.86 Mn | 13.18 Mn | 84.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.80 Mn |
| Dec 31, 2025 | 95.94 Mn |
| Sep 30, 2025 | 84.11 Mn |
| Jun 30, 2025 | 81.32 Mn |
| Mar 31, 2025 | 77.98 Mn |
| Dec 31, 2024 | 80.82 Mn |
| Sep 30, 2024 | 73.50 Mn |
| Jun 30, 2024 | 69.30 Mn |
| Mar 31, 2024 | 69.04 Mn |
| Dec 31, 2023 | 48.71 Mn |
| Sep 30, 2023 | 61.73 Mn |
| Jun 30, 2023 | 81.23 Mn |
| Mar 31, 2023 | 90.66 Mn |
| Dec 31, 2022 | 104.23 Mn |
| Sep 30, 2022 | 79.80 Mn |
| Jun 30, 2022 | 74.17 Mn |
| Mar 31, 2022 | 75.31 Mn |
| Dec 31, 2021 | 80.68 Mn |
| Sep 30, 2021 | 57.45 Mn |
| Jun 30, 2021 | 48.25 Mn |